ProShares Ultra Nasdaq Biotechnology

Most Recent

  • uploads///dna _
    Company & Industry Overviews

    Major Biotech ETFs Had Lackluster Performance in the Past Month

    The SPDR S&P Biotech ETF (XBI) is trading at a PE ratio of 20.4x. It reported a one-year return of ~19.7% and a three-year return of ~10.9%.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Must-Know Developments for Ionis Pharmaceuticals

    Ionis entered a collaborative agreement with Suzhou Ribo Life Science for the development and commercialization of RNA-targeted therapeutics in China in April 2017.

    By Mike Benson
  • uploads///anr
    Company & Industry Overviews

    What Are Analysts Saying about Horizon Pharma?

    According to a Thomson Reuters Eikon consensus of six brokerage firms on December 17, 2016, 83.3% of the firms rated Horizon Pharma (HZNP) a “buy.”

    By Jillian Dabney
  • uploads///Actimmune trials
    Company & Industry Overviews

    Horizon Pharma’s Steep Fall in December: What Happened?

    On December 8, 2016, Horizon Pharma (HZNP) announced that its Phase 3 STEADFAST trial for Actimmune didn’t meet its primary endpoint. Horizon stock fell 22.5% that day.

    By Jillian Dabney
  • uploads///horizon as orphan drug company
    Company & Industry Overviews

    Buy Allows Horizon to Further Expand into Orphan Drug Space

    Through the acquisition of Raptor Pharmaceuticals, Horizon Pharma (HZNP) will gain access to Procysbi and Quinsair and expand in the orphan drug space.

    By Jillian Dabney
  • uploads///LSD portfolio
    Earnings Report

    How Will Shire’s LSD Portfolio Perform in 2016?

    Shire’s (SHPG) LSD (or lysosomal storage disorders) portfolio consists of Elaprase, Replagal, and Vpriv.

    By Jillian Dabney
  • uploads///shp
    Company & Industry Overviews

    How Does Shire’s Late-Stage Pipeline Look?

    SHP643, a phase three candidate, might present significant growth potential for Shire (SHPG) in the hereditary angioedema (or HAE) space.

    By Jillian Dabney
  • uploads///JZP
    Company & Industry Overviews

    Could JZP-110 Offset Xyrem’s Probable Sales Decline?

    Jazz Pharmaceuticals (JAZZ) acquired the rights to develop, manufacture, and market JZP-110 from Aerial BioPharma in January 2014.

    By Jillian Dabney
  • uploads///lialda
    Company & Industry Overviews

    Shire Won Patent Infringement Case for Lialda

    In fiscal 2015, Lialda added $684.4 million to Shire’s (SHPG) top line, reflecting an 8% annual increase in sales. This was supported by a 10% rise in prescription volume.

    By Jillian Dabney
  • uploads///NPS Pharma acquisition
    Company & Industry Overviews

    How Has Shire Benefited from NPS Pharmaceuticals Acquisition?

    In February 2015, Shire (SHPG) completed its acquisition of NPS Pharmaceuticals for $5.2 billion. Through the merger, Shire gained access to Gattex and Natpara.

    By Jillian Dabney
  • uploads///baxalta sales
    Company & Industry Overviews

    How Could Baxalta Acquisition Become a Catalyst for Shire?

    Shire’s (SHPG) acquisition of Baxalta could prove to be a catalyst for Shire’s valuation in the near term. The combined entity is expected to record revenues of $20 billion by fiscal 2020.

    By Jillian Dabney
  • Financials

    Must-know: Are market valuations stretched?

    The NASDAQ Biotechnology Index (IBB) is up 14% this year—less than a third of its 122 companies earned any money in the last 12 months.

    By Russ Koesterich, CFA
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.